Clinical Biomarkers and Companion Diagnostics Summit Europe on April 08-10, 2025 in London, United Kingdom

With drug-diagnostic co-development partnerships fueling advances in diagnostic testing for Alzheimer’s, Multiple Sclerosis, cardiovascular disease, rare genetic disorders, and cancer, 2025 is poised as a critical year for Europe’s precision medicine community. However, developing, clinically validating, regulatory filing and commercialising biomarkers and in vitro diagnostics remains no easy feat, as knowledge gaps persist in validating surrogate endpoints, co-developing scalable diagnostic testing workflows and infrastructure, navigating reimbursement pathways, and harmonising drug-diagnostic IVDR-adherence for approval in unmet patient need.

The 15th World Clinical Biomarkers and Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. Serving as your premium connection-making platform, this summit will unite over 170 key European stakeholders to accelerate precision drugs from discovery through to commercialisation for patients in need.

URLs:

Tickets: https://go.evvnt.com/2843562-2?pid=10008

Brochure: https://go.evvnt.com/2843562-3?pid=10008

Time: 5:00 PM - 5:00 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): GBP 0.50,

Drug Developer Pricing - 2 Day Pass (Conference Only): GBP 0.50,

Solution Provider Pricing - 2 Day Pass (Conference Only): GBP 3099.00

Speakers: Andrea Stevens, Senior Director Precision Medicine Access, Johnson and Johnson Innovative Medicine, Anne-Laure Bauchet, Immunohistochemistry Team Manager and Translational Medicine Lead, Sanofi, Annick Sawala, Head of Translational Research, Vivan Therapeutics, Antje Lukas, Senior Director, Regulatory Affairs Companion Diagnostics, Daiichi Sankyo Europe, Catarina Veiga, Commercial Director, Pharma Business, Platomics, Cheryl McFarlane, Associate Director, Assay Development and Validation, Almac Diagnostic Services, Christian Ruzanski, Principal Scientist, Novo Nordisk, Daniel Gehrlach, Director, Biomarkers, HMNC Brain Health, Huw Bannister, Senior Director of Digital and Computational Pathology, AstraZeneca, James Duboff, Director, Strategic Partnerships, Genomics England, James Hewitt, IVD Business Line Manager and Senior Specialist (CDx), TÜV SÜD, Jens Kieckbusch, Director, External Innovation Precision Medicine, GlaxoSmithKline, Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS, Katarzyna Witkowska, Strategic Partnerships Director, Genomics England, Kristina McGuire, Executive Director and Head, Precision Medicine Laboratory Operations and Companion Diagnostics, Regeneron, Lien Dejager, Biomarker Lead, argenx, Lill-Brith von Arx, RWE Northern Europe Hub Lead, Eli Lilly and Co., Mario Richter, Senior Director, Development Sciences, AbbVie, Matthew Binns, Access and Pricing Leader, Neurology and Rare Diseases, UCB, Monika Lamba Saini, Global Translational Pathology Leader and Education Committee Member, ADC Therapeutics and Digital Pathology Association, Naureen Starling, Medical Oncologist GI and Director of the Royal Marsden’s Clinical Trials Unit, NIHR Professor of Gastrointestinal Oncology, The Royal Marsden NHS Foundation Trust, Patrick Fivey, Director, Precision Medicine Policy, AstraZeneca, Philipp Schatz, Global Regulatory Lead, IVD, Bayer, Robert Thong, Co-Founder and Chief Executive Officer, MultiOmic Health, Shane McGann, Vice President, Regulatory Affairs, Mythic Therapeutics, Sharon Liang, Executive Director, Head of Precision Medicine and Digital Health, Bristol Myers Squibb, Subrata Bose, Vice President and Head Of General Clinical Imaging Services, Diagnostic Imaging, Data and Artificial Intelligence, Bayer, Varun Pattani, Senior Director, Diagnostic Development, Clinical and Scientific Operations, Foundation Medicine, Vincent Mikol, Global Head of Translational Medicine, Sanofi